Anacor Pharmaceuticals, which is developing treatments for nail fungus and psoriasis using boron-based chemistry, will see its quiet period end on Sunday, January 2. On November 23, the company raised $60 million by offering 12 million shares at $5, below the range of $16-$18. Citi and Deutsche Bank Securities acted as lead managers on the deal.
